cro quality benchmarking – phase i service … · accelovance 3 altasciences (vince, algorithme)...
TRANSCRIPT
CRO QUALITY BENCHMARKING – PHASE I SERVICE PROVIDERS (10TH EDITION)
JUNE, 2018
WORLDWIDE CLINICAL TRIALS COMPANY PERFORMANCE PROFILE, EXCERPT FROM CRO QUALITY BENCHMARKING - PHASE I SERVICE PROVIDERS, 10TH EDITION
2ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
Cue the streamers. Don the party hats. Break out the champagne.
That’s right, folks. We’ve been bringing you top notch CRO performance and selection data for an entire decade now. Welcome to the 10th edition of ISR’s CRO Quality Benchmarking - Phase I Service Providers report.
As ever, the goal of this report is to provide detailed information to aid in making informed decisions when outsourcing Phase I work. No doubt the CRO selection process is an onerous one; reviewing proposals, whittling providers down to a short list, and hearing bid defenses are time consuming and result in a lot of information to digest. And don’t even get us started on contract negotiations. This report aims to simplify the process of provider selection by offering insights into the selection process and service provider performance.
305 qualified Phase I decision-makers participated in our survey to share their insights on topics such as selection drivers, perceptions of providers, and how well provider performance stacked up against their expectations. 46 Phase I providers received performance evaluations on 22 attributes across five categories (Budget Factors, Delivery Factors, Staff Characteristics, Accessibility, and Services). Based on customer feedback, ISR has introduced the Services scorecard this year. Respondents who have recent experience using a CRO for Central lab, Biostatistics, Data management, and/or Monitoring services rate how well providers performed on those specific services. These metrics will be particularly useful to sponsors looking to outsource work functionally or needing a provider with stand-out capabilities in one of these areas.
This report is valuable for both sponsors and service providers. Sponsors – use this information to understand the drivers that industry peers feel are important when selecting Phase I CROs. Search for CROs that may be a good fit for your needs after understanding how they performed for others along the dimensions most critical to your projects. Providers – learn how sponsors select CROs in different decision-making scenarios so that you may tailor your proposals to appropriately trumpet the desired capabilities. Gain a better understanding of your strengths and weaknesses as seen through the eyes of your recent customers. See where other providers might hold competitive advantages and analyze service gaps that may need to be closed.
For sponsors and service providers alike, the information contained in this report is useful for making educated decisions regarding Phase I outsourced work. Let ISR’s ten years of experience in this arena do the legwork for you.
IN THIS EXCERPT: The content for this excerpt was taken directly from CRO Quality Benchmarking - Phase I Service Providers report, June 2018. All or parts of the following sections are included in this excerpt: ISR Introduction, Methodology, Participant Criteria, Service Provider Performance and Loyalty Primary Section Takeaways, Company Service Quality Profiles, Worldwide Clinical Trials Performance Summary, Performance Across Service Providers, and About ISR.
INTRODUCTION
3ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
METHODOLOGY
D A T A C O L L E C T I O N I N Q 4 , 2 0 1 7
3 0 - M I N U T E W E B - B A S E D Q U A N T I T A T I V E S U R V E Y
3 0 5 R E S P O N D E N T S F R O M N O R T H A M E R I C A , E U R O P E , A N D A S I A
4ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
Respondents were required to pass several screening criteria to qualify and participate in this survey:
• Must work at a pharmaceutical company, biotech company, or medical device company
• Must have responsibility in at least one of several relevant areas. For example, Clinical Operations, Project Management, Executive Management, or Research and Development Management
• Must have involvement with outsourced Phase I trials within past 12 months
Consolidation is nothing new to the contract services industry, and a number of companies featured in this report have been part of recent M&A activity. At ISR we know that integration of a new acquisition can take a significant amount of time; as such, companies acquired within the past 18-24 months are still represented by the prior brand.
Participant Criteria
5ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
Service ProviderRespondent Ratings
Accelovance 3
Altasciences (Vince, Algorithme) 6
BioPharma Services Inc. 8
Bioskin 5
Biotrial 10
Celerion 26
CHDR 8
Chiltern 11
Clinical Research Services (CRS) 5
Clinlogix 4
Covance 94
DataCeutics 3
DaVita Clinical Research 12
DCRI-Duke 12
Eurofins 22
Eurotrials 3
Frontage 10
ICON 59
Inamed 3
INC Research 35
inVentiv Health Clinical 45
IQVIA/QuintilesIMS 85
Lambda 10
Service ProviderRespondent Ratings
Medpace 18
Medsource 4
NAMSA 5
Novotech 7
Nuvisan 10
Ora 5
PAREXEL 99
Pharm-Olam International 6
PPD 73
PRA 42
PRC Clinical 2
ProTrials 3
QPS 4
Quotient Clinical 19
Rho 5
SGS Life Sciences 12
Simbec 2
Spaulding Clinical 5
SynteractHCR 3
TKL Research 4
US Oncology 8
WCCT Global 13
Worldwide Clinical Trials 19
Total Ratings 847
Companies listed in bold print have been reviewed by 10 or more respondents. These providers have detailed company service quality profiles and are included in an in-depth performance analysis.
Number of Ratings Per Company
6ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
SERVICE PROVIDER PERFORMANCE AND LOYALTY
CRO QUALITY BENCHMARKING – PHASE I SERVICE PROVIDERS (10TH EDITION)
7ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
Primary Section Takeaways1. Top Performers:
• Overall: Worldwide Clinical Trials, Biotrial, SGS Life Sciences
• Budget Factors: Worldwide Clinical Trials, Nuvisan, Lambda
• Delivery Factors: Biotrial, Worldwide Clinical Trials, SGS Life Sciences, Celerion
• Staff Characteristics: Worldwide Clinical Trials, Biotrial, DCRI-Duke, SGS Life Sciences
• Accessibility: Biotrial, SGS Life Sciences, Worldwide Clinical Trials
• Services: Worldwide Clinical Trials, inVentiv Health Clinical, Celerion
2. Customer Loyalty:
• 2018 Top Performers: Worldwide Clinical Trials, Celerion, SGS Life Sciences, Biotrial
• 3-Year Rolling Average Top Performers: Worldwide Clinical Trials, SGS Life Sciences, Celerion, DaVita Clinical Research, Quotient Clinical
8ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
CRO QUALITY BENCHMARKING – PHASE I SERVICE PROVIDERS (10TH EDITION)
COMPANY SERVICE QUALITY PROFILES
9ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
Worldwide Clinical Trials(Base=19)
Loyalty Component Scores
Performance Relative to Expectations
CRO QUALITY BENCHMARKING – PHASE I SERVICE PROVIDERS (10TH EDITION) 151
Worldwide Clinical Trials (n=19)
Loyalty Component Scores
Performance Relative to Expectations
8.1
8.2
8.2
1 2 3 4 5 6 7 8 9 10
Overall satisfaction
Likelihood to use again
Likelihood to recommend
18%
27%
25%
17%
11%
11%
11%
11%
11%
11%
11%
16%
21%
11%
11%
16%
16%
21%
21%
21%
16%
21%
9%
18%
8%
8%
11%
11%
16%
16%
16%
16%
16%
11%
11%
26%
26%
21%
21%
16%
16%
16%
26%
32%
73%
55%
67%
75%
63%
79%
63%
68%
68%
74%
74%
74%
68%
63%
63%
63%
63%
58%
63%
63%
53%
42%
16%
5%
5%
5%
5%
5%
5%
5%
0% 20% 40% 60% 80% 100%
Central lab (n=11)
Biostatistics (n=11)
Data management (n=12)
Monitoring (n=12)
Technology for real-time access to data
Access to "unique" tests, machines, equipment
Cost
Appropriateness of change orders
Patient/volunteer recruitment
Local market/Regulatory knowledge
Data quality
Therapeutic expertise
Operational excellence
Access to patient populations
Staff turnover
Project manager quality
Scientific knowledge of the Phase I unit's lead investigator
Easy to work with
Timely project communications
Meeting overall project timelines
Clinic availability
Responsiveness
% of Respondents
Greatly exceeded my expectationsSomewhat exceeded my expectationsMet my expectationsSomewhat fell short of my expectationsGreatly fell short of my expectations
CRO QUALITY BENCHMARKING – PHASE I SERVICE PROVIDERS (10TH EDITION) 151
Worldwide Clinical Trials (n=19)
Loyalty Component Scores
Performance Relative to Expectations
8.1
8.2
8.2
1 2 3 4 5 6 7 8 9 10
Overall satisfaction
Likelihood to use again
Likelihood to recommend
18%
27%
25%
17%
11%
11%
11%
11%
11%
11%
11%
16%
21%
11%
11%
16%
16%
21%
21%
21%
16%
21%
9%
18%
8%
8%
11%
11%
16%
16%
16%
16%
16%
11%
11%
26%
26%
21%
21%
16%
16%
16%
26%
32%
73%
55%
67%
75%
63%
79%
63%
68%
68%
74%
74%
74%
68%
63%
63%
63%
63%
58%
63%
63%
53%
42%
16%
5%
5%
5%
5%
5%
5%
5%
0% 20% 40% 60% 80% 100%
Central lab (n=11)
Biostatistics (n=11)
Data management (n=12)
Monitoring (n=12)
Technology for real-time access to data
Access to "unique" tests, machines, equipment
Cost
Appropriateness of change orders
Patient/volunteer recruitment
Local market/Regulatory knowledge
Data quality
Therapeutic expertise
Operational excellence
Access to patient populations
Staff turnover
Project manager quality
Scientific knowledge of the Phase I unit's lead investigator
Easy to work with
Timely project communications
Meeting overall project timelines
Clinic availability
Responsiveness
% of Respondents
Greatly exceeded my expectationsSomewhat exceeded my expectationsMet my expectationsSomewhat fell short of my expectationsGreatly fell short of my expectations
© Industry Standard Research
© Industry Standard Research
CRO QUALITY BENCHMARKING – PHASE II/III SERVICE PROVIDERS (10TH EDITION)
54
Accell (Base=2)
Loyalty Component Scores
Performance Relative to Expectations
7.0
7.0
6.5
1 2 3 4 5 6 7 8 9 10
Overall satisfaction
Likelihood to use again
Likelihood to recommend
50%
100%
100%
50%
50%
50%
50%
50%
50%
50%
50%
50%
100%
50%
50%
100%
100%
100%
100%
100%
100%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
0% 20% 40% 60% 80% 100%
Central lab (n=2)
Data management (n=1)
Monitoring (n=1)
Investigator recruitment (n=1)
Patient recruitment
Speed of site start-up
Local market/Regulatory knowledge
Easy to work with
Operational excellence
Therapeutic expertise
Project manager quality
Staff turnover
Cost
Appropriateness of change orders
Technology for real-time access to data
Data quality
Responsiveness
Study design expertise
Timely project communications
Meeting overall project timelines
% of Respondents
Greatly exceeded my expectationsSomewhat exceeded my expectationsMet my expectationsSomewhat fell short of my expectationsGreatly fell short of my expectations
10ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
Performance Across Service ProvidersThis “cross-CRO” chart has been developed as a way for pharma companies and CROs to quickly gauge how CROs perform against their peers on a specific performance attribute.
The metrics used in the following chart assign 3 points if respondents indicated the service provider greatly exceeded expectations, 1 point if they somewhat exceeded expectations, 0 points if they met expectations, -1 point if they somewhat missed expectations and -3 points if they greatly missed ex-pectations.
A service provider’s scores are included on this chart if 10 or more respondents evaluate its performance on that attribute. Numbers are colored green if the score is >0.25 and red if the score is <-0.25.
11ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
World
wid
e Clin
ical T
rials
(n=19
)
CRO G
CRO H
CRO I
CRO J
CRO F
CRO E
CRO D
CRO C
CRO B
CRO A
Access to “unique” tests, machines, equipment
0.42 0.07 0.42 0.06 0.20 -0.05 0.07 0.07 -0.07 0.50 -0.10
Access to patient populations
0.58 0.08 0.38 0.06 -0.30 0.00 0.20 0.10 0.12 -0.10 -0.10
Appropriateness of change orders
0.42 -0.18 -0.15 -0.11 0.20 -0.14 0.18 -0.13 -0.20 0.20 0.10
Clinic availability 0.68 0.22 0.38 0.00 0.50 0.14 0.29 0.18 0.05 -0.10 -0.20
Cost 0.26 -0.25 0.19 -0.10 0.60 -0.29 0.24 -0.28 -0.22 -0.30 0.50
Data quality 0.47 0.18 0.35 0.11 0.10 0.02 0.31 0.06 0.10 0.30 0.00
Easy to work with 0.74 0.16 0.54 0.14 0.70 -0.05 0.31 0.04 0.20 0.30 0.00
Local market/ Regulatory knowledge
0.47 0.05 0.19 0.16 -0.10 0.19 0.20 0.02 0.03 0.10 0.20
Meeting overall project timelines
0.79 0.04 0.46 0.00 0.40 -0.12 0.27 0.04 0.05 0.20 0.00
Operational excellence 0.74 0.12 0.46 0.10 0.10 0.02 0.20 0.05 -0.03 0.10 0.20
Patient/volunteer recruitment
0.42 0.07 0.46 0.08 0.10 0.19 0.33 0.12 0.03 0.00 -0.20
Project manager quality 0.68 0.01 0.27 0.16 0.40 -0.14 0.47 0.04 0.08 0.40 0.30
Responsiveness 0.89 0.15 0.42 0.12 0.50 -0.02 0.38 0.13 0.17 0.20 -0.10
Scientific knowledge of the Phase I unit’s lead investigator
0.68 0.07 0.31 0.13 0.40 0.00 0.22 0.17 0.12 0.10 0.00
Staff turnover 0.58 -0.05 0.12 -0.15 0.00 0.07 0.22 -0.17 -0.14 0.20 0.10
Technology for real- time access to data
0.26 0.04 0.23 0.12 -0.20 0.10 0.36 0.05 0.02 0.10 0.30
Therapeutic expertise 0.58 0.18 0.27 0.09 -0.10 0.12 0.31 0.15 0.17 0.20 0.20
Timely project communications
0.79 -0.03 0.23 0.03 0.40 -0.05 0.36 0.07 0.08 0.30 -0.10
Central lab 0.64 0.29 0.37 0.11 0.08 0.56 0.10 0.11
Biostatistics 1.00 0.17 0.26 0.02 0.14 0.44 -0.07 0.03
Data management 0.83 0.20 0.05 0.01 0.15 0.39 0.08 0.05
Monitoring 0.58 0.17 0.24 0.03 0.10 0.17 0.04 0.08
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
12ISRreports.com ©2018 CRO Quality Benchmarking – Phase I Service Providers (10th edition)
CRO K
CRO R
CRO S
CRO T
CRO U
CRO Q
CRO P
CRO O
CRO N
CRO M
CRO L
Access to “unique” tests, machines, equipment
0.75 0.17 0.15 0.30 0.06 0.42 0.18 0.17 0.14 0.08 0.14
Access to patient populations
0.58 0.17 0.23 0.80 0.06 0.21 0.45 0.11 0.00 0.33 -0.06
Appropriateness of change orders
0.08 -0.08 0.00 -0.10 -0.18 0.11 0.18 0.06 0.09 0.00 -0.23
Clinic availability 0.42 0.08 0.31 0.70 0.01 0.00 0.45 0.11 0.09 0.00 0.06
Cost 0.33 -0.08 -0.23 0.20 -0.13 0.00 0.18 0.00 0.23 -0.08 -0.09
Data quality 0.58 0.08 0.15 0.60 0.08 0.11 0.00 0.11 0.18 0.08 0.03
Easy to work with 0.33 -0.08 0.38 0.80 -0.01 0.63 0.09 0.00 0.41 0.33 0.40
Local market/ Regulatory knowledge
0.42 0.00 0.15 0.50 0.18 0.37 0.45 0.17 0.09 0.00 0.03
Meeting overall project timelines
0.42 -0.08 0.00 0.80 -0.01 0.53 0.09 -0.06 0.18 0.33 0.11
Operational excellence 0.67 0.08 0.08 0.40 0.09 0.32 0.27 0.06 0.09 0.08 0.06
Patient/volunteer recruitment
0.42 -0.42 0.23 0.70 0.08 0.26 0.27 0.06 0.05 0.17 0.14
Project manager quality 0.50 -0.33 -0.23 0.50 -0.01 0.58 0.36 -0.22 0.18 0.33 0.14
Responsiveness 0.50 0.08 0.23 0.60 0.13 0.47 0.18 0.22 0.18 0.50 0.11
Scientific knowledge of the Phase I unit’s lead investigator
0.17 0.25 -0.15 1.00 -0.05 0.05 0.00 0.22 0.36 0.50 0.14
Staff turnover 0.08 -0.17 0.15 0.40 -0.24 0.11 -0.18 0.06 0.05 0.33 -0.17
Technology for real- time access to data
0.58 -0.08 0.15 0.40 0.08 -0.21 0.09 0.17 0.00 -0.17 0.00
Therapeutic expertise 0.58 0.42 0.23 0.60 0.14 0.37 0.55 0.33 0.05 0.75 0.14
Timely project communications
0.50 -0.25 0.08 1.00 0.01 0.47 0.09 0.22 0.09 0.33 0.09
Central lab -0.08 0.00 -0.07 0.22 0.25
Biostatistics -0.02 -0.08 0.00
Data management -0.02 -0.07 -0.10 -0.04
Monitoring 0.07 0.00 0.00 0.08
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
NOTENOUGH
DATA
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit our website at ISRreports.com, email [email protected], or follow us on Twitter @ISRreports.
Send Us Your Feedback Because we are a service organization, we enjoy receiving feedback on our work. Please e-mail any comments, questions, or suggestions to [email protected].
Copyright 2018 Industry Standard Research. All rights reserved. “Act with confidence”, ISR Reports and Industry Standard Research are trademarks of Industry Standard Research. All other trademarks are property of their respective holders. Information is subject to change since Industry Standard Research reserves the right to make changes without notice. While the information contained herein has been prepared from sources deemed to be reliable, Industry Standard Research reserves the right to revise the information without notice but has no obligation to do so. Use of this information is at your sole discretion. For more information, contact Industry Standard Research at 1-919-230-0106. Printed in the USA June, 2018.
ABOUT US